News

Given that over 50% of women experience at least one urinary tract infection annually and antimicrobial resistance is on the rise, it's essential to evaluate the evidence for potential non-drug interventions.

Recent analysis suggests that stricter COVID-19 measures could have saved thousands, Danjuma Adda calls for more funding and awareness to tackle viral hepatitis, our second episode of From Pathogen to Infectious Disease podcast, and more this week.

The prevalence of methicillin-resistant Staphylococcus aureus has surged from 2.58% to 14.79%, highlighting a need for updated treatment strategies.

A large English study shows the incidence rates of arterial thromboses and venous thrombotic events decreased after immunization.

In the second episode with Michael Laposata, MD, PhD, he discusses how lab professionals can communicate with infectious disease clinicians, how AI can be used in diagnostics, and potential point-of-care diagnostic opportunities for the lab.

Providing nirsevimab (Beyfortus) to all newborns and high-risk infants during the 2024-2025 RSV season represents an advancement in protecting infant health.

Increased funding can lead to the development of resources like rapid diagnostic test kits and improve the overall availability of treatment for those in need.

Here is a review of the most up-to-date information around the infection.

Omadacycline (Nuzyra) maintained its potency over time and did not show a decrease in effectiveness.

HepB-BD is unavailable in 17 countries, and the number of young children receiving the HepB3 shot has dropped by 10 percentage points or more.

A bill in the House of Representatives was just introduced with the advocacy of the Peggy Lillis Foundation in hopes of bringing more recognition and research to the healthcare-associated infection.

A hospital CDI intervention program that supported patients via an ID specialist demonstrated clinical benefits compared to another hospital where patients were followed by providers of any specialty.

New study reveals a marked reduction in HCV infection rates, falling from 23.4% in 2017 to 6% in 2023.

New funding will go towards research around a specific molecule that has been shown to lower inflammation.

Malaria control efforts can be impacted by indoor nuisance pest management as ineffective control of pests may erode community trust in vector control products.

A new study looks at the role of genetics in the leveling degrees of infection.

A new analysis says if all states imposed such measures it would have saved thousands of lives.

A secondary analysis of a randomized trial points to limited benefits on the microbiota.

Boar’s Head is recalling its liverwurst product as well as other deli meats due to concerns around contamination.

Merck’s antibody, clesrovimab (MK-1654), is designed to protect infants against medically attended lower respiratory infections (MALRI) caused by RSV.

This week, NYC has revealed high rates of Hepatitis C virus reinfection, SHEA tackles antimicrobial resistance amidst challenges during the COVID-19 pandemic, and more this week from Contagion.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

Three studies provide insights into the ongoing COVID-19 pandemic, the prevalence of post-COVID conditions among primary care patients, the effectiveness of nirmatrelvir/ritonavir treatment, and declines in primary care visits.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.